Nyxoah completed approximately $110M in June financing, combining a $95M equity raise with a €13.8M second tranche from its European Investment Bank loan facility. The capital addresses a pressing funding need. As of March 31st, the company held €25.9M in cash against a quarterly operating loss near €20M, with management flagging going-concern doubt and a runway extending only into Q3 2026. The new financing is aimed primarily at the US commercial launch of Genio, its hypoglossal nerve stimulation system for obstructive sleep apnea, which received FDA approval in August 2025.

Nyxoah priced a $95M underwritten public offering of 55.2M ordinary shares at $1.72, alongside the start of a transition to a US-based CEO. The company develops the Genio system, a hypoglossal nerve stimulation device for obstructive sleep apnea, and is positioning for US commercial scale-up. The capital raise and leadership shift together frame that pivot toward the US market following regulatory progress.